Company intelligence / Profile preview
Laboratorios Poen
- Ownership
- Private
- Development stage
- Commercial
Overview
Laboratorios Poen has a broad commercial portfolio of prescription and over-the-counter ophthalmic products, including innovative preservative-free glaucoma treatments and lubricating eye drops. The company also offers nutritional supplements for ocular health. No clinical trial data or investigational pipeline was identified in public sources. Recent expansion includes acquisition of Dromex Biotech’s plant to increase manufacturing capacity. Products such as XEGREX LC® for glaucoma and GOTA-PC® for dry eyes are available commercially. No published clinical results were found.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule (most ophthalmic drugs are small molecules)Nanoemulsion (for certain formulations)Gel-based drug delivery therapyOintment-based drug delivery therapyNutritional supplement (capsules)
- Industry
- Biotech
Drug pipeline
1 assetBeyond the preview
Go deeper on Laboratorios Poen.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Laboratorios Poen.